To: Tadsamillionaire who wrote ( 300) 6/28/2006 7:46:26 PM From: Tadsamillionaire Respond to of 347 GenoMed Can Explain Link Between West Nile, Diabetes/Hypertension ST. LOUIS, June 26 /PRNewswire-FirstCall/ -- GenoMed (Pink Sheets: GMED), a Next Generation Disease Management company whose business is global public health(TM), today announced that it has already published why patients with diabetes and high blood pressure should be at increased risk of getting West Nile virus encephalitis. This observation has now been made in California, New York and Texas. The link appears to be over-activity of the angiotensin I-converting enzyme, abbreviated 'ACE.' In 2002, GenoMed published a series of four papers showing that over- activity of ACE led to diabetes and hypertension, as well as to complications like heart and kidney disease. Using the right dose of the right ACE inhibitor, it was possible to reverse diabetic or hypertensive kidney disease for the first time. In 2004, GenoMed published that a similar approach was successful in treating over 80% of patients with West Nile virus encephalitis. GenoMed's treatment success rate for WNV encephalitis is currently 86% (19 of 22 patients improved rapidly). In 2003, GenoMed filed patent applications claiming that ACE inhibitors and angiotensin II blockers may be a near-universal viral antidote, because previously healthy people who get sick from nearly all viral diseases suffer from a 'cytokine storm' initiated by too much angiotensin II. Angiotensin II is made by ACE. GenoMed's viral antidote was included in the Project BioShield II Act of 2005, since it would be an ideal public health response to viral bioterrorism. Said Dr. Moskowitz, GenoMed's CEO and Chief Medical Officer, 'GenoMed goes from the molecular mechanism of disease directly to practical treatments that are safe and useful at the population level. It's very gratifying to get separate epidemiologic confirmation that we've discovered something huge.'